Zealand Pharma A/S · OMXCOP:ZEAL

Zealand Pharma A/S — Investor Day (2015)

23 slides from Zealand Pharma A/S's investor day presentation, 2015

  1. Slide 1: ZP4207 – A novel, stable glucagon analogue for hypoglycemia

    ZP4207 – A novel, stable glucagon analogue for the treatment and control of hypoglycemia By Adam Steensberg, SVP and CMO Zealand Pharma A/S page 1

  2. Slide 2: Treat-to-target in Type 1 and Type 2 diabetes

    Treat-to-target in Type 1 and Type 2 diabetes Type 1 diabetes  1.25 million patients in the US1  About 320,000 patients are on CSII/Pumps2 Tighter glycemic Type 2 diabetes control in large  Over half or 11.9 million patients are on OADs only cohort studies is  3.1 million are on combination ther

  3. Slide 3: Severe hypoglycemia in diabetes remains a challenge

    Severe hypoglycemia in diabetes remains a challenge 282,000 annual visits to the emergency room due to acute hypoglycemic events1 Type 1 diabetes: 115 to 320 events per 100 patient-years2 Type 2 diabetes: 35 to 70 events per 100 patient-years2 Sources: 1.Center for Disease Control and Prevention.cdc

  4. Slide 4: Risk of severe hypoglycemia associated with insulin therapy is a significant concern

    Risk of severe hypoglycemia associated with insulin therapy is a significant concern among patients 64% of T1D patients are very afraid of experiencing ADA and EASD recommend that all a severe hypoglycemic patients on insulin therapy carry a episode1 glucagon hypoglycemia rescue kit. Only 20-25% of

  5. Slide 5: Current rescue kits are difficult to use

    Current rescue kits are difficult to use “……. the complexity of the kit is a problem”1 Among hypoglycemic posts in internet forums intimidating, usability and syringe were most often associated with the word hypokit1 Source: 1. Research Commissioned by Zealand Pharma n = 11.373 hypoglycemia posts in

  6. Slide 6: US glucagon market opportunity

    US glucagon market opportunity  The glucagon market is under-penetrated and over-complicated  Rescue kits accounts for about 60% of Value growth (USD million) market value as generated from 140 drugstores, long term care and clinics1 120 132 100 108 80 60  About 40% of the value is from the non-

  7. Slide 7: ZP4207 - More Awareness. Less Fear

    ZP4207 - More Awareness. Less Fear Zealand Pharma A/S page 7

  8. Slide 8: Design a glucagon analogue for liquid formulation

    Design a glucagon analogue for liquid formulation 9-step rescue kits Ready-to-use rescue pen » For illustration only Zealand Pharma A/S page 8

  9. Slide 9: Need for a stable glucagon analogue for better treatment of hypoglycemia

    Need for a stable glucagon analogue for better treatment of hypoglycemia Single-dose formulation for: Multiple-dose formulation for: Ready-to-use rescue pen Mini-dose pen for treatment of mild to moderate hypoglycemia For illustration only For illustration only Ready-to-use glucagon analogue in a vi

  10. Slide 10: The challenge: Native glucagon is unstable in liquid formulation

    The challenge: Native glucagon is unstable in liquid formulation Native glucagon forms fibrils within a day in liquid formulations1 » ZP4207 shows superior stability compared to native glucagon1 » Sources: 1. Samples was incubated in microtiter plates at 28ºC with fluorescents reading every 10 min b

  11. Slide 11: ZP4207 has superior physical and chemical stability

    ZP4207 has superior physical and chemical stability No formation of fibrils with long-term storage in liquid formulations » Chemical stability significantly improved compared to native glucagon1 » Source: 1. Data from prior lad – ZP-GA-1 Zealand Pharma A/S page 11

  12. Slide 12: Phase I: Safe and well tolerated in healthy volunteers

    Phase I: Safe and well tolerated in healthy volunteers  64 healthy volunteers  Treated with single-ascending doses of ZP4207 or marketed glucagon product  Objective: To evaluate safety and tolerability (PE) and various PK-PD measurements of ZP4207 compared to native glucagon ZP4207 increases bloo

  13. Slide 13: Phase I: Safe and well tolerated in T1D patients

    Phase I: Safe and well tolerated in T1D patients  20 patients with Type 1 diabetes  Treated with single dosing of ZP4207 in a cross-over design with glucagon as a comparator  Objective: To evaluate PK-PD measures of ZP4207 ZP4207 and its’ effect to increase blood glucose levels after insulin indu

  14. Slide 14: Outlook for ZP4207 single-use formulation

    Outlook for ZP4207 single-use formulation Development plans FDA response to pre-IND Next clinical trial H1 2016 Potential future product offerings Ready-to-use rescue pen Ready-to-use in a vial For illustration only Zealand Pharma A/S page 14

  15. Slide 15: ZP4207 multiple-dose formulation for control of mild to moderate hypoglycemia

    ZP4207 multiple-dose formulation for control of mild to moderate hypoglycemia Mini-dose pen for mild to moderate hypoglycemia Provides insulin users a new modality to increase low blood sugar and optimize glycemic control » For illustration only Dual-hormone artificial pancreas device ZP4207 multipl

  16. Slide 16: Artificial Pancreas for optimized diabetes treatment

    Artificial Pancreas for optimized diabetes treatment Insulin pump Blood glucose sensor 2015 2015 Insulin pump Continuous with sensor BGM 2008 Insulin pump 1980’s Sensor 1985 First insulin pen adjustable dose Insulin 1973 1923 Discovery of insulin Syringe + vial Insulin device development Manual home

  17. Slide 17: It's a balancing act

    It’s a balancing act - current systems only include insulin Low Blood glucose High Sensor Glucagon Insulin For illustration only Zealand Pharma A/S page 17

  18. Slide 18: Pancreas' role in healthy individuals

    Pancreas’ role in healthy individuals Rising blood sugar GLUCAGON Liver Pancreas INSULIN Tissue Declining blood sugar Zealand Pharma A/S page 18

  19. Slide 19: Functionality of the dual hormone pump system

    Functionality of the dual hormone pump system Rising blood sugar GLUCAGON Liver INSULIN Tissue Declining blood sugar Zealand Pharma A/S page 19

  20. Slide 20: Dual hormone artificial pancreas for optimal diabetes treatment

    Dual hormone artificial pancreas for optimal diabetes treatment Insulin pump Blood glucose sensor Glucagon pump 2015 2015 Insulin pump Continuous with sensor BGM 2008 Glucagon analogue in liquid formulation 2015 Insulin pump 1980’s 1985 First insulin pen adjustable dose 1973 Lyophilized glucagon pow

  21. Slide 21: Phase Ib: ZP4207 is safe and well-tolerated after repeat dosing

    Phase Ib: ZP4207 is safe and well-tolerated after repeat dosing Phase Ib trial design  24 healthy volunteers  Three cohorts of different daily doses of ZP4207, each Grant from Helmsley over 5 days Initial clinical and  Objective: preclinical activities o Primarily: To evaluate safety and tolerabi

  22. Slide 22: Planned outlook for ZP4207 multiple-use formulation

    Planned outlook for ZP4207 multiple-use formulation Chronic toxicology studies ongoing ZP4207 ready for clinical trials with Dual- For illustration only hormone Artificial Pancreas Devices Mini-dose Pen for For illustration only treatment of mild to moderate hypoglycemia opportunity being evaluated

  23. Slide 23: Need for a stable glucagon analogue for better treatment of hypoglycemia

    Need for a stable glucagon analogue for better treatment of hypoglycemia Single-dose formulation for: Multiple-dose formulation for: Ready-to-use rescue pen Mini-dose pen for treatment of mild to moderate hypoglycemia For illustration only For illustration only Ready-to-use glucagon analogue in a vi

Zealand Pharma — Investor Day (2015) on 6ix